Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC sees further upside at M&S as momentum builds

(Sharecast News) - RBC Capital Markets has reiterated its 'outperform' rating for Marks & Spencer, saying the the business is well positioned to defy sector concerns. As of Friday's close, M&S shares had fallen around 7% so far this year, with investors worried about more aggressive pricing tactics by Asda on M&S's food operations.

However, RBC believes these concerns are "likely overdone", with M&S having the least customer overlap with Asda compared with the other major food retailers. The broker explained that Asda tends to cater for lower-income customers doing a weekly big shop, whereas M&S customers visit for convenience food, last-minute dinners and/or special occasions.

Also, M&S's 50:50 Ocado Retail joint venture should provide more top-line growth, with nearly a third of Ocado Retail sales coming from M&S products.

For the company's clothing and home divisions, RBC said M&S is "pushing on well in areas of existing strength", like knitwear, denim and lingerie, while an improved sourcing outlook - 80% of its clothing is sourced in USD with 80% of FX hedged on a 12 to 18-month basis - should help support margins.

"At 12x CY25 P/E we see potential for further upside as investors reappraise the durability of its growth and exposure to favourable trends, including a flight to quality in food and clothing," the broker said.

M&S shares were down 2.5% at 353.87p by 1156 GMT, outperforming the wider FTSE 100 which was down 4%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.